Stock Ticker

  • Loading stock data...

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) Showcases Results From trial Examining Patient and Physician Experiences And Perceptions With IBS-C

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) reported new findings showcasing the frustration of patients suffering from IBS-C and the viewpoint of healthcare providers who cure these patients. The web questionnaire, intended to advance a better understanding of the attitudes and experiences associated with IBS-C, disclosed numerous patients experienced lost productivity and stress when managing this problem. HCPs and Patients also reported a lack of satisfaction in presently available prescription treatments for IBS-C.

The details

Detailed data from the BURDEN IBS-C trial were presented at World Congress of Gastroenterology at American College of Gastroenterology, in Orlando, Fla. Data is based on results from the web questionnaire of over 325 HCPs and 1,300 patients. IBS-C shows a negative impact on a person’s day-to-day life, including productivity.

Almost two out of three patients described IBS-C indications as somewhat to extremely bothersome. As many as 43% of patients reported they had felt frustrated with IBS-C, with over a quarter of respondents reporting their condition was stressful.

Patients stated that their productivity at school or work is impacted 4 out of every 30 days monthly by IBS-C, with respondents missing around 1.5 school or work days per month following this condition. HCPs noted patients’ frustration with IBS-C indications, yet underestimate the number of patients that have accepted their condition.

The majority of HCPs noted that their patients were stressed (65%) and frustrated (76%) by indications of IBS-C. HCPs were less likely to note that patients were accepting of the impact of their problem, compared to the 39% of people who expressed they had permitted their IBS-C.

Many patients and HCPs feel prevailing treatments do not sufficiently resolve IBS-C indications. Among the people that were currently utilizing a prescription IBS-C treatment, 78% were not entirely satisfied. Over 51% of these patients mentioned efficacy as a reason for not being entirely satisfied with prevailing prescription IBS-C treatments.

Published by Van Bettauer

Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https://plus.google.com/100770875710593766367/posts

Recent Stories

Sponsored Content

Sign Up To Get Our Latest Stocks Alerts